Login to Your Account

Clinic Roundup

Tuesday, May 14, 2013
• Mirna Therapeutics Inc., of Austin, Texas, has initiated a Phase I study of MRX34, the first miRNA to advance to a clinical trial for cancer. The trial is being conducted in patients with unresectable primary liver cancer or metastatic cancer with liver involvement.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription